Towards new targets for the treatment of pulmonary arterial hypertension : Importance of cell-cell communications

• Published in: Biologie aujourd'hui Vol. 210; no. 2; p. 65
• Main Authors: Tu, Ly, Ghigna, Maria-Rosa, Phan, Carole, Bordenave, Jennifer, Le Hiress, Morane, Thuillet, Raphaël, Ricard, Nicolas, Huertas, Alice, Humbert, Marc, Guignabert, Christophe
• Format: Journal Article
• Language: French
• Published: France 2016
• Subjects: Bone Morphogenetic Protein Receptors, Type II - physiology; Cell Communication - physiology; Humans; Hypertension, Pulmonary - immunology; Hypertension, Pulmonary - metabolism; Hypertension, Pulmonary - therapy; Molecular Targeted Therapy - methods; Molecular Targeted Therapy - trends; Nerve Tissue Proteins - physiology; Potassium Channels, Tandem Pore Domain - physiology; Signal Transduction - physiology
• ISSN: 2105-0686

Pulmonary arterial hypertension (PAH) is a disorder in which mechanical obstruction of the pulmonary vascular bed is largely responsible for the rise in mean pulmonary arterial pressure (mPAP), resulting in a progressive functional decline despite current available therapeutic options. There are multiple mechanisms predisposing to and/or promoting the aberrant pulmonary vascular remodeling in PAH, and these involve not only altered crosstalk between cells within the vascular wall but also sustained inflammation and dysimmunity, cell accumulation in the vascular wall and excessive activation of some growth factor-stimulated signaling pathways, in addition to the interaction of systemic hormones, local growth factors, cytokines, and transcription factors. Heterozygous germline mutations in the bone morphogenetic protein receptor, type-2 (BMPR2) gene, a gene encoding a receptor for the transforming growth factor (TGF)-β superfamily, can predispose to the disease. Although the spectrum of therapeutic options for PAH has expanded in the last 20 years, available therapies remain essentially palliative. Over the past decade, however, a better understanding of key regulators of this irreversible remodeling of the pulmonary vasculature has been obtained. New and more effective approaches are likely to emerge. The present article profiles the innovative research into novel pathways and therapeutic targets that may lead to the development of targeted agents in PAH.